New drug avasopasem joins fight against metastatic breast cancer

NCT ID NCT07137871

Recruiting now Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding avasopasem to standard hormone therapy and a CDK4/6 inhibitor can help women with metastatic hormone receptor-positive breast cancer that has stopped responding to treatment. The study will enroll 35 participants and focus on safety, while also checking if the combination improves tumor control. Avasopasem has shown anti-tumor effects with low toxicity in earlier research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avasopasem (also called GC4419)
What this could lead to: If it works, this could improve the effectiveness of standard hormone therapy and CDK4/6 inhibitors for metastatic breast cancer, potentially slowing disease progression.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Disease Progression hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC

Contacts and locations

Locations

Mays Cancer Center, UT Health San Antonio
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.